Ipsen (IPNN) Stock Price & Analysis
IPNN Stock Chart & Stats
- Day’s Range
- MXN 3,384.27 - MXN 3,384.27
- 52-Week Range
- MXN 2,617.44 - MXN 3,384.27
- Previous Close
- MXN 3,384.27
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 274.40B
- Enterprise Value
- MXN 12.99B
- Total Cash (Recent Filing)
- MXN 1.97B
- Total Debt (Recent Filing)
- MXN 963.20M
- Price to Earnings (P/E)
- 25.4
- Beta
- 0.11
- Next Earnings
- Feb 11, 2027 (Est.)
- EPS Estimate
- 165.34
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.87%
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth
Steady multi-year revenue expansion indicates sustained demand for Ipsen’s specialty medicines and growing commercial reach. Continued top-line growth can support investment in clinical development, lifecycle management, and commercial capabilities across oncology, rare diseases, and neuroscience.
Healthy Profitability
Ipsen remains meaningfully profitable despite margin pressure, with a 30% EBITDA margin providing operating capacity to fund innovation and commercialization. This profitability supports resilience across its specialty portfolio and gives management flexibility to pursue durable growth opportunities.
Conservative Leverage
Low leverage and a growing equity base provide Ipsen with a relatively resilient financial structure. This reduces balance-sheet strain, preserves borrowing capacity for strategic investment, and improves the company’s ability to absorb operating volatility while continuing to develop specialty medicines.
Bears Say
Margin Compression
The substantial decline in net margin shows that revenue growth has not translated into stable profitability at prior levels. If higher costs or unfavorable product mix persist, Ipsen may have less earnings available for research, commercial investment, and shareholder returns.
Sharp Debt Increase
The sharp year-over-year increase in total debt weakens an otherwise conservative capital structure and raises the importance of future deleveraging or sustained cash generation. Higher obligations could constrain capital allocation if operating performance or cash conversion becomes less consistent.
Cash-Flow Volatility
The strong 2025 cash-flow rebound is encouraging, but the prior weakness and inconsistent relationship between operating cash flow and profitability indicate execution or working-capital variability. Such volatility can complicate funding of research, acquisitions, and other long-term priorities.
Ipsen News
IPNN FAQ
What was Ipsen’s price range in the past 12 months?
What is Ipsen’s market cap?
When is Ipsen’s upcoming earnings report date?
How were Ipsen’s earnings last quarter?
Is Ipsen overvalued?
Does Ipsen pay dividends?
What is Ipsen’s EPS estimate?
How many shares outstanding does Ipsen have?
What happened to Ipsen’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ipsen?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Ipsen
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- David G. Loew
- Employees
- 5,535
- Website
- www.ipsen.com
- Address
- 70 rue Balard, Paris, IF, 75015, FR
Ipsen (IPNN) Earnings & Revenues
IPNN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 0 | 1 |
| Technical Analysis | 2 | 0 | 1 |
| Moving Averages | 12 | 0 | 0 |







